SCHEMBL675671

SCHEMBL675671

CCCC(N)Cc1ccc2c(n1)[nH]c1ccc(C=Cc3ccc(OC)cc3)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.37
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TUBB1 Q9H4B7 2/20 0.36
GLA P06280 2/20 0.34
RELA Q04206 2/20 0.33
CYP2D6 P10635 1/20 0.33
DRD1 P21728 1/20 0.33
HTR2A P28223 1/20 0.33
ADORA1 P30542 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675100 0.89 IP6K1 (0.37) ALKGLARELACYP2D6KDM4E
SCHEMBL677055 0.87 ALK (0.37) ALKTAS1R3TAS1R1TUBB1GLA
SCHEMBL674941 0.87 ALK (0.38) ALKCYP2D6DRD1HTR2AADORA1
SCHEMBL675011 0.82 ALK (0.37) ALKTAS1R3TAS1R1TUBB1GLA
SCHEMBL3725133 0.82 GHSR (0.42) ALKTUBB1GLATUBB4ATUBB
SCHEMBL3725135 0.82 GHSR (0.42) ALKTUBB1GLATUBB4ATUBB
SCHEMBL675668 0.80 TAS1R3 (0.37) ALKTAS1R3TAS1R1TUBB1GLA
SCHEMBL675669 0.78 ALK (0.38) ALKTUBB1GLARELATUBB4A
SCHEMBL676564 0.77 IP6K1 (0.37) ALKTUBB1RELATUBB4ATUBB
SCHEMBL675412 0.76 NPC1 (0.47) ALKTUBB1GLARELACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 ALK 1/4885TAS1R3 3700/4885TAS1R1 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.